Cargando…
Biosimilar and Follow-on Insulin: The Ins, Outs, and Interchangeability
Objective: To provide an overview of the differences between biosimilars and generics, and to summarize regulatory requirements and outstanding issues related to biosimilar insulins in the United States, including the issue of interchangeability. Data Sources: References were obtained using MEDLINE...
Autores principales: | White, John, Goldman, Jennifer |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6313268/ https://www.ncbi.nlm.nih.gov/pubmed/34861004 http://dx.doi.org/10.1177/8755122518802268 |
Ejemplares similares
-
The Automatic Substitution of Biosimilars: Definitions of Interchangeability are not Interchangeable
por: Afzali, Anita, et al.
Publicado: (2021) -
Focus on biosimilar etanercept – bioequivalence and interchangeability
por: Cantini, Fabrizio, et al.
Publicado: (2018) -
Interchangeability of Biosimilars: What Level of Clinical Evidence is Needed to Support the Interchangeability Designation in the United States?
por: Alvarez, Daniel F., et al.
Publicado: (2020) -
An Update Review of Biosimilars of Adalimumab in Psoriasis – Bioequivalence and Interchangeability
por: Zhou, Xin, et al.
Publicado: (2021) -
Biosimilar and interchangeable: Inseparable scientific concepts?
por: de Mora, Fernando, et al.
Publicado: (2019)